Downregulation of lysine‑specific demethylase 1 enhances the sensitivity of hormone‑sensitive prostate cancer cells to androgen deprivation therapy

Wang,Min; Liu,Xiuheng; Chen,Zhiyuan; Zhang,Lu; Weng,Xiaodong

doi:10.3892/ol.2020.12354

Downregulation of lysine‑specific demethylase 1 enhances the sensitivity of hormone‑sensitive prostate cancer cells to androgen deprivation therapy

Authors:
- Min Wang
- Xiuheng Liu
- Zhiyuan Chen
- Lu Zhang
- Xiaodong Weng
View Affiliations

Affiliations: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: December 6, 2020 https://doi.org/10.3892/ol.2020.12354
Article Number: 93
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysine‑specific demethylase 1 (LSD1) plays an important role in androgen receptor (AR) signaling, and LSD1 levels are associated with prostate cancer (PCa) progression. The present study investigated the association between the downregulation of LSD1 and the proliferation and invasiveness of PCa cells, as well as the effect of LSD1 on the androgen deprivation therapy (ADT)‑induced apoptosis of PCa cells. The effect of the inhibition of LSD1 combined with ADT on PCa cell apoptosis was characterized. Furthermore, the mechanisms underlying LSD1‑mediated apoptosis induced by ADT in PCa cells were investigated. Downregulation of LSD1 impaired the proliferation and invasiveness of PCa cells. Moreover, downregulation of LSD1 enhanced the apoptosis of PCa cells induced by bicalutamide in vitro. Downregulation of LSD1 decreased PSA expression, increased caspase 3 and Bax expression, decreased Bcl‑2 expression and consequently enhanced castration‑induced PCa cell apoptosis in vivo. These findings indicated that downregulation of LSD1 could effectively enhance the efficacy of ADT for hormone‑ sensitive PCa, demonstrating that this could be a promising adjunctive therapy with ADT for this disease.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zeng H, Zou X, Zhang S and He J: Report of Cancer Incidence and Mortality in China, 2011. China Cancer. 24:1–10. 2012. View Article : Google Scholar
3	Larsson R, Mongan NP, Johansson M, Shcherbina L, Abrahamsson PA, Gudas LJ, Sterner O and Persson JL: Clinical trial update and novel therapeutic approaches for metastatic prostate cancer. Curr Med Chem. 18:4440–4453. 2011. View Article : Google Scholar : PubMed/NCBI
4	Rice MA, Malhotra SV and Stoyanova T: Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 9:8012019. View Article : Google Scholar : PubMed/NCBI
5	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al TAX 327 Investigators, : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
6	Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et al: Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 34:1402–1418. 2016. View Article : Google Scholar : PubMed/NCBI
7	Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D and Scher HI: Long-term safety and antitumor activity in the Phase1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 68:795–801. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al COU-AA-302 Investigators, : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar : PubMed/NCBI
9	Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, et al COU-AA-302 Investigators, : Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16:152–160. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, et al Southwest Oncology Group Trial 9346 (INT-0162), : Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 24:3984–3990. 2006. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI
12	Wang M, Liu X, Jiang G, Chen H, Guo J and Weng X: Relationship between LSD1 expression and E-cadherin expression in prostate cancer. Int Urol Nephrol. 47:485–490. 2015. View Article : Google Scholar : PubMed/NCBI
13	Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z and He L: Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 467:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
14	Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 437:436–439. 2005. View Article : Google Scholar : PubMed/NCBI
15	Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S, et al: Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 464:792–796. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, et al: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66:11341–11347. 2006. View Article : Google Scholar : PubMed/NCBI
17	Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G and Berman DM: Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 27:7180–7191. 2008. View Article : Google Scholar : PubMed/NCBI
18	Green SM, Mostaghel EA and Nelson PS: Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 360:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
19	Knudsen KE, Arden KC and Cavenee WK: Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem. 273:20213–20222. 1998. View Article : Google Scholar : PubMed/NCBI
20	Xu Y, Chen SY, Ross KN and Balk SP: Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 66:7783–7792. 2006. View Article : Google Scholar : PubMed/NCBI
21	Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, et al: p53 is regulated by the lysine demethylase LSD1. Nature. 449:105–108. 2007. View Article : Google Scholar : PubMed/NCBI
22	Scoumanne A and Chen X: The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 282:15471–15475. 2007. View Article : Google Scholar : PubMed/NCBI
23	Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, et al: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res. 69:2065–2071. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al: Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 128:574–586. 2011. View Article : Google Scholar : PubMed/NCBI
25	Bennani-Baiti IM, Machado I, Llombart-Bosch A and Kovar H: Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol. 43:1300–1307. 2012. View Article : Google Scholar : PubMed/NCBI
26	Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, et al: Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 9:1618–1627. 2014. View Article : Google Scholar : PubMed/NCBI
27	McConkey DJ, Orrenius S and Jondal M: Cellular signalling in programmed cell death (apoptosis). Immunol Today. 11:120–121. 1990. View Article : Google Scholar : PubMed/NCBI
28	Strobel T, Swanson L, Korsmeyer S and Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA. 93:14094–14099. 1996. View Article : Google Scholar : PubMed/NCBI
29	Antonsson B and Martinou JC: The Bcl-2 protein family. Exp Cell Res. 256:50–57. 2000. View Article : Google Scholar : PubMed/NCBI
30	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
31	Lin T, Ponn A, Hu X, Law BK and Lu J: Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene. 29:4896–4904. 2010. View Article : Google Scholar : PubMed/NCBI